|
|
||||||||
1 From the Departments of Mechanical and Industrial Engineering and 2 Ophthalmology, University of Toronto, Ontario, Canada.
| Abstract |
|---|
|
|
|---|
METHODS. After baseline facility measurement in human eye bank eyes (n = 10 pairs), one eye of each pair received anterior chamber exchange and continued perfusion with medium containing 10 mg/ml cationic ferritin. Contralateral eyes were treated in a similar manner with anionic ferritin (10.0 or 102 mg/ml). Eyes were fixed by anterior chamber exchange and perfusion with universal fixative at 8 mm Hg (corresponding to a physiologic pressure of 15 mm Hg in vivo) and examined by transmission electron microscopy. In a second series of human eyes (n = 8 pairs), facility was measured before and after anterior chamber exchange, with a solution containing 0.1 U/ml neuraminidase.
RESULTS. Perfusion of eyes with anionic ferritin at either 10.0 or 102 mg/ml caused a negligible 2% increase in facility, whereas cationic ferritin perfusion reduced facility by 66% (P < 0.00001). Perfusion with fixative reduced facility by approximately 60% in both cationic and anionic ferritin-perfused eyes, relative to facilities after perfusion with ferritin. Transmission electron microscopy showed that the distribution of ferritin was segmentally variable. Cationic ferritin consistently labeled the luminal surface of the inner wall of Schlemms canal, and variably labeled the juxtacanalicular connective tissue (JCT) and trabecular beam surfaces. Anionic ferritin was more prominent in the JCT and intertrabecular spaces and less so on the luminal surface of Schlemms canal. By scanning electron microscopy, cationic ferritin was seen to accumulate at intercellular margins of the inner wall. Neuraminidase perfusion had no significant effect on outflow facility.
CONCLUSIONS. Cationic ferritin reduces outflow facility, presumably by binding to negatively charged sites in the outflow pathway. A possible mechanism is partial or complete blockage of intercellular clefts in the inner wall of Schlemms canal by the ferritin that accumulates on the luminal surface of the inner wall. Although they are possible targets for ferritin binding, sialyl residues themselves seem to have little direct effect on outflow facility. Our data indicate that positively charged molecules, especially if they can interact with inner wall pores, have the potential to markedly alter outflow facility.
| Introduction |
|---|
|
|
|---|
Charged moieties within the juxtacanalicular connective tissue (JCT) and on Schlemms canal endothelium have been hypothesized to play a role in determining aqueous outflow facility.1 2 In particular, Tripathi et al.3 have suggested that differences in sialic acid content between normal and glaucomatous eyes play a role in ocular hypertension. Normal and glaucomatous human eyes showed different patterns of cationic ferritin (CF) labeling after postmortem perfusion,4 possibly related to differences in the distribution of charged species within the outflow tract.
In unrelated work, we discovered that CF perfusion markedly affects the outflow facility of human eyes. The goal of the present work was to investigate this effect in detail. First, we compared the effects of CF and anionic ferritin (AF) perfusion on outflow facility. Second, we examined the distribution of these tracers in the outflow tissues of perfused eyes. Third, we studied the effects of neuraminidase, an enzyme that hydrolyzes sialyl residue linkages, on outflow facility. Taken together, these studies were meant to improve our understanding of how charged moieties influence aqueous outflow facility.
| Methods |
|---|
|
|
|---|
Ostensibly normal human eyes were obtained within 24 hours after the donors death (n = 10 pairs). The mean donor age was 70.3 years (range, 4085) and the mean time after death to the start of perfusion was 21.1 hours (range, 1125 hours). Baseline facility was measured for 60 to 90 minutes by perfusion into the posterior chamber with DBG. All perfusions were performed at a constant pressure of 8 mm Hg (corresponding to 15 mm Hg in vivo), using previously described techniques.5 At the completion of baseline facility measurement, one eye of each pair received anterior chamber exchange with a solution of 10.0 mg/ml CF. Contralateral eyes were treated in a similar manner with either 10.0 or 102 mg/ml AF. Care was taken during the anterior chamber exchange to maintain a constant IOP of 8 mm Hg. Eyes were then further perfused with their respective ferritin solutions at 8 mm Hg for 60 to 90 minutes, while facility was measured.
We also obtained one pair of POAG-affected eyes (donor age, 88 years) perfused 24 hours after death. They were perfused with 10 mg/ml CF and 102 mg/ml AF, as described for the remaining eyes.
We present the facility data in two ways. The first is by simple averaging of facility data between eyes, with the resultant values reported as mean ± SEM. The second is by normalizing the raw facility data, thereby allowing comparison of relative facility changes between pairs of eyes. Normalization involved dividing the measured facility at each time for a given eye by the average facility reading for that eye in the 30-minute period before anterior chamber exchange with ferritin. The percentage facility change due to ferritin (or fixative) perfusion was then computed as 100 · (Cnorm,pre - Cnorm,post), where Cnorm,pre and Cnorm,post are the normalized facilities before and after ferritin (or fixative) exchange, respectively. The statistical significance of facility changes due to ferritin (or fixative) was computed from a paired two-tailed Students t-test using the percentage normalized facility change as the statistic of interest.
Neuraminidase Perfusion and Facility Measurements
Two types of neuraminidase were used: from Clostridium
perfringens (Boehringer-Mannheim, Laval, Quebec, Canada; catalog
number 1585 886) and from Arthrobacter ureafaciens
(Boehringer-Mannheim; catalog number 269 611). Lyophilized powder was
dissolved in DBG+0.3% weight bovine serum albumin (BSA; Sigma) to make
a stock solution of 1 U/ml. Working solutions of 0.1 U/ml were then
made up by dilution of stock solutions with DBG+0.3% BSA, and the pH
was adjusted to 5.9 by titration with HCl. This pH is in the middle of
the optimal range for enzyme activity. Supplementary data from the
manufacturer on the neuraminidase preparation from C.
perfringens indicated that the enzyme had some protease
contamination (as much as 7.6 U protease per mg lyophilizate), whereas
the preparation from A. ureafaciens was essentially protease
free (<0.02 U protease/mg lyophilizate).
The concentration of neuraminidase was based on measurements by Tripathi et al.,1 who state that the human trabecular meshwork contains 3.6 micromoles sialic acid per gram wet weight. Considering the meshwork to have a cross-sectional (flow-wise) area of 0.05 to 0.13 cm26 and an average internalexternal thickness of 200 µm, we estimated the wet weight of the meshwork to be approximately 1 to 3 mg, which corresponds to a total sialic acid content of approximately 4 to 11 nanomoles. One unit of the enzyme liberates 1 micromole of sialic acid per minute by hydrolyzing terminal bonds joining sialic acid to oligosaccharides, glycoproteins, and glycolipids. Considering the duration of exposure (typically several hours) and the continual flushing of the meshwork with new perfusate, we estimated that the described concentration of neuraminidase would be sufficient to largely hydrolyze bonds, attaching the sialyl residues within the meshwork.
The perfusion protocol was identical with that used for the ferritin experiments, except that the eyes received neuraminidase instead of ferritin. Specifically, in four pairs of eyes, one eye received neuraminidase from C. perfringens, and the contralateral eye received vehicle (DBG+0.3% weight BSA, pH adjusted to 5.9). In two pairs of eyes, one eye received neuraminidase from A. ureafaciens and the contralateral eye received vehicle. Finally, in two pairs of eyes, one eye received neuraminidase from C. perfringens, and the contralateral eye received neuraminidase from A. ureafaciens. The mean donor age for this group of eyes was 83.1 years (range, 7292), and the mean time after death was 21.5 hours (range, 1226).
Neuraminidase activity was verified using a fluorometric in vitro assay
based on the liberation of methylumbelliferone (MU) from
2'-(4-methylumbelliferyl)-
-D-N-acetylneuraminic
acid (MU-NANA).7
8
MU-NANA (0.4 ml of 0.25 mM; Toronto
Research Chemicals, Toronto, Ontario, Canada) in 50 mM sodium phosphate
buffer (pH 5.0) was incubated with 1 µl neuraminidase solution for 1
minute at 37°C, followed by addition of 0.6 ml 1 M sodium carbonate
solution. After approximately 4 minutes, the stabilized fluorescence
signal was read with a fluorescence spectrophotometer (QM-1; Photon
Technology International, Lawrenceville, NJ), using excitation and
emission wavelengths of 390 nm and 450 nm, respectively. Both enzyme
types were assayed at concentrations of 0.0125, 0.05, and 0.1 U/ml,
spanning the range of concentrations expected to occur in perfused
eyes. All readings were corrected for background fluorescence, by using
a control assay without enzyme.
Morphology
At the conclusion of facility measurement after ferritin
perfusion, seven pairs of eyes were fixed by anterior chamber exchange
and perfusion with universal fixative (2.5% paraformaldehyde, 2.5%
glutaraldehyde in Sörensens buffer) at 8 mm Hg for 60 to 90
minutes, followed by overnight immersion fixation. The remaining eyes
(n = 3 pairs) were lightly fixed by anterior chamber
exchange and perfusion with universal fixative at 2 to 3 mm Hg for only
15 minutes, followed by overnight immersion fixation.
Tissue was processed for transmission electron microscopy (TEM). Briefly, radial segments of the limbal area were dissected, postfixed in 1% osmium tetroxide, dehydrated, infiltrated, and embedded in Epon-Araldite. Some ultrathin sections were stained with uranyl acetate and lead citrate, whereas other sections were not stained. Use of unstained samples allowed clear and definitive visualization ferritin particles within the extracellular matrix of the JCT. Adjacent tissue samples were microdissected and processed by conventional methods9 to produce scanning electron microscopic montages of the inner wall of Schlemms canal.
| Results |
|---|
|
|
|---|
|
|
Facility Effects of Neuraminidase
Both neuraminidase preparations showed an approximately linear
doseresponse curve over the concentration range from 0 to 0.1 U/ml in
the in vitro assay and the expected amount of total activity. The
activity of the enzyme from C. perfringens was approximately
50% higher than that from A. ureafaciens. We conclude that
the enzyme preparations we used had biological activity.
In eyes perfused with neuraminidase from C. perfringens, there was a time-dependent increase in facility for 3 to 4 hours after anterior chamber exchange. After 180 minutes of neuraminidase perfusion, the net facility increase was 71% ± 18% (mean ± SEM), which was different from zero at P = 0.03. However, similar perfusions with neuraminidase from A. ureafaciens (negligible protease contamination) showed no significant increase in facility (net increase of only 4%). This was consistent with experiments in which the two types of neuraminidase were perfused into paired eyes: the eyes perfused with neuraminidase from C. perfringens showed a mean facility increase of 71% when compared with eyes perfused with neuraminidase from A. ureafaciens. Although a relatively small number of eyes were perfused in this part of the study, the results are therefore consistent with a facility effect from the protease-contaminated neuraminidase but no effect from the protease-free enzyme preparation.
Morphologic Findings in Ferritin-Perfused Eyes
By TEM, cationic and AF showed markedly different distribution
patterns within the meshwork, similar to those reported by deKater et
al.4
Generally speaking, both AF and CF distributions were
highly variable, with some regions showing extremely dense labeling and
others showing little or no labeling (Figs. 2
and 3)
. The CF was usually present as clumps, whereas the AF was more
punctate and uniform.
|
|
In AF-perfused eyes, there was much less ferritin coating on the inner wall of Schlemms canal on the luminal surface (Fig. 3) . Giant vacuoles were sometimes entirely filled with AF, and the JCT frequently demonstrated extremely heavy labeling, particularly at the higher concentration (102 mg/ml) of AF. However, even at this high concentration, there were always some giant vacuoles and regions of the JCT that were entirely devoid of label (Fig. 3A , right side). AF was only very rarely seen in intercellular clefts between inner wall cells (Fig. 3C) . AF was observed in the extracellular matrix immediately under the inner wall, where the accumulation seemed similar to that observed for CF (Fig. 3C) . Particularly striking was the distribution of AF in the corneoscleral meshwork, where the majority of the intertrabecular spaces were completely and densely filled with AF (Figs. 3A 3B) .
Scanning electron microscopic examination of the inner wall of Schlemms canal showed significant differences between AF- and CF-perfused eyes. In CF-perfused eyes, most regions of the inner wall showed some ferritin decoration. Most frequently, this took the form of discrete ferritin clumps (Fig. 4) . The intercellular margins were often prominently elevated above the surrounding endothelial surface in CF-perfused eyes (Fig. 4) . This seemed to be due to accumulation of ferritin at the margin of the inner wall cells and lifting of the overlying cell where inner wall cells overlapped one another at their margins. In AF-perfused eyes, we observed only very infrequent and sparse ferritin accumulation on the inner wall, and the intercellular borders looked similar to those previously reported in control eyes (Fig. 5) .
|
|
|
| Discussion |
|---|
|
|
|---|
Of these two possibilities, we think that the first is unlikely. The cationization procedure acts by modifying the carboxyl terminals of the native ferritin subunits10 and as such is not expected to markedly change protein configuration. This is supported by measurements of the diffusion coefficient and Stokes radius of both types of ferritin, which show that the hydrodynamic characteristics of the two molecules are not significantly different from one another.11 Further, the clumping of CF that we observed would be expected to produce a lower flow resistance (per unit mass of ferritin) than the more homogeneous distribution seen with AF, because clumping invariably produces ferritin-poor channels through which flow can pass. In short, AF should be at least as hydrodynamically resistant as CF, per unit mass of ferritin.
It therefore seems that the different effects that CF and AF have on facility are best explained by preferential accumulation of CF in a location that is effective at blocking aqueous outflow. This is consistent with the very rapid time course of CF-induced facility alterations, pointing to a hydrodynamic blockage effect by accumulating CF molecules. In this regard it is noteworthy that the one location where CF was more consistently seen than AF was on the luminal surface of the inner wall of Schlemms canal. This luminal accumulation of CF was most striking along the intercellular junctions, and seems to be consistent with observations of CF clumps near the mouths of inner wall openings (pores), although identification of such pores was usually not unambiguous (e.g., Fig. 6 , right panel).
If it is accepted that aqueous humor passes through pores of the inner wall, often associated with intercellular junctions,12 then accumulation of ferritin at or over these locations would be expected to have a significant effect on outflow resistance, because the pores typically account for only approximately 0.1% of the inner wall surface9 and represent "funnels"13 or choke points where outflow can be relatively easily obstructed. The implication is that any substance that interacts with these pores to increase their resistance can very effectively reduce aqueous outflow facility. Negatively charged glycoproteins are thought to be present in the intercellular cleft of microvascular endothelia, particularly near the luminal surface, and are thought to play a central role in controlling the permeability of such endothelia.14 If similar glycoproteins were present in the intercellular clefts between inner wall endothelium, then it seems plausible that cationic molecules with large Stokes radii (hydrodynamic resistance) could bind to negative sites on the glycoproteins and efficiently block intercellular pores.
Our facility results are qualitatively and quantitatively consistent with experimental data from a study in which Turner et al.15 perfused frog mesenteric capillaries with CF and AF. In this system, perfusion with CF with concentrations in the range of 1 to 25 mg/ml caused the hydraulic permeability of the vessel wall to be reduced by 70% (compared with 66% in our system), whereas perfusion with AF had minor effects on hydraulic permeability. Turner et al. also observed CF and AF labeling patterns on the capillary endothelium very similar to those reported in the current study. Our observed patterns are also consistent with studies by Rounds and Vaccaro,16 who showed an intrinsic preference for CF to bind to the luminal (vs. the abluminal) surface of rat capillary endothelium.
Perfusions with protease-free neuraminidase did not show any significant effect on outflow facility. This does not prove that sialic acid residues do not influence outflow facilityfor example, binding of charged moieties to sialyl residues could indirectly alter outflow facility. However, it suggests that acute alteration of sialic acid residue levels does not alter facility per se.
It is noteworthy that the percentage of facility reduction due to fixative infusion was almost identical in the AF- and CF-perfused eyes. Although it is not understood how fixation changes outflow facility, this result gives us some insight into meshwork function. More specifically, it implies that fixation effects in these eyes depended on the outflow resistance before fixation. This rules out a scenario in which fixation increases the resistance of one part of the meshwork, while CF increases the resistance of a second part that does not hydrodynamically interact with the first part. In such a noninteracting model, the magnitude of the resistance increase due to fixation would be independent of resistance increase due to ferritin, which was not observed. We conclude that fixation and CF must be interacting somehow. Perhaps fixation affects the flow resistance of the JCT and ferritin affects the pores of the inner wall, with interaction occurring through a funneling effect.13
It is remarkable how segmentally variable the CF distribution was and how CF was never seen filling the lumens of giant vacuoles, even though AF usually filled these lumens. We do not have a good explanation for these effects, which were first reported by deKater et al.4 Because the hydrodynamic properties of CF and AF are similar, it seems probable that CF and AF were carried into the meshwork in a similar way during perfusion. Differences between CF and AF distributions (and possibly segmental variations) might therefore reflect the ability of the tissue to bind and/or retain the tracer.
In summary, CF markedly reduced outflow facility in human eyes, possibly due to preferential accumulation of CF molecules at one or more critical locations in the outflow system. Our data suggest that intercellular clefts (pores) of the inner wall of Schlemms canal are a likely site of CF accumulation and flow resistance increase. Note that this does not imply that intercellular clefts have significant flow resistance under normal circumstances (i.e., in the absence of CF), but it suggests that cationic entities can lower outflow facility by blocking such sites.
| Acknowledgements |
|---|
| Footnotes |
|---|
Supported by Grant MA-10051 from the Medical Research Council of Canada and the Glaucoma Research Society of Canada.
Submitted for publication January 16, 2001; accepted February 16, 2001.
Commercial relationships policy: N.
The publication costs of this article were defrayed in part by page
charge payment. This article must therefore be marked
"advertisement" in accordance with 18 U.S.C.
1734
solely to indicate this fact.
Corresponding author: C. Ross Ethier, Department of Mechanical and Industrial Engineering, 5 Kings College Road, University of Toronto, Toronto, Ontario M5S 3G8, Canada. ethier{at}mie.utoronto.ca
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
K. E. Keller, J. M. Bradley, M. J. Kelley, and T. S. Acott Effects of Modifiers of Glycosaminoglycan Biosynthesis on Outflow Facility in Perfusion Culture Invest. Ophthalmol. Vis. Sci., June 1, 2008; 49(6): 2495 - 2505. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. Hann, C. K. Bahler, and D. H. Johnson Cationic Ferritin and Segmental Flow through the Trabecular Meshwork Invest. Ophthalmol. Vis. Sci., January 1, 2005; 46(1): 1 - 7. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. Ethier, A. T. Read, and D. Chan Biomechanics of Schlemm's Canal Endothelial Cells: Influence on F-Actin Architecture Biophys. J., October 1, 2004; 87(4): 2828 - 2837. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. K. Bahler, C. R. Hann, M. P. Fautsch, and D. H. Johnson Pharmacologic Disruption of Schlemm's Canal Cells and Outflow Facility in Anterior Segments of Human Eyes Invest. Ophthalmol. Vis. Sci., July 1, 2004; 45(7): 2246 - 2254. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Alvarado, A. Betanzos, L. Franse-Carman, J. Chen, and L. Gonzalez-Mariscal Endothelia of Schlemm's canal and trabecular meshwork: distinct molecular, functional, and anatomic features Am J Physiol Cell Physiol, March 1, 2004; 286(3): C621 - C634. [Abstract] [Full Text] |
||||
![]() |
M. Johnson, D. Chan, A. T. Read, C. Christensen, A. Sit, and C. R. Ethier The Pore Density in the Inner Wall Endothelium of Schlemm's Canal of Glaucomatous Eyes Invest. Ophthalmol. Vis. Sci., September 1, 2002; 43(9): 2950 - 2955. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |